Professor J. Edwin Blalock

In 1987, Professor J. Edwin Blalock of the University of Alabama conceived the idea of a novel way of producing an anti-idiotypic vaccine to cure autoimmune diseases. The technique was patented on 18 May 1993, under US patent number 5,212,072.

To test this concept, Professor Blalock selected myasthenia gravis (MG) because it is well documented and understood, has an identifiable and measurable antibody level and testing could be carried out using appropriate animal models (rats) that closely simulate the human disease.

The vaccine was highly effective.

A study on natural occuring MG in dogs was carried between 1997 and 2003. The study began because of the persistence of one individual pet owner from Florida. Having been told that her dog was a victim of MG and that the outlook was bleak, she questioned and investigated vigorously until hearing of Professor Blalock's work with rats. At this point she persuaded Professor Blalock to try the vaccine on her dog that was subsequently cured. A trial on more dogs was then decided.  The results will soon be published in a peer reviewed scientific journal.
 

click here to watch the video of the MGFA 2002

click here to watch the Questions & Answers with Professor J. Edwin Blalock
 
Here under is a link to Prof. J. Edwin blalock CV
 
 Dr. Stéphane Huberty

Dr Stéphane Huberty is Chief Executive Officer of CuraVac. He is a medical doctor who has studied the research of Professor Blalock for personal reasons, as a sufferer from myasthenia gravis - now held under control through medication. Dr. Huberty is also a proven and successful entrepreneur. He founded and is CEO of IDEAS in Belgium, a company specializing in CAD/CAM design of customized orthopedic and normal footwear. IDEAS is active in more than 20 countries worldwide.